Neurovascular Devices Market Forecasts to 2028 – Global Analysis By Product (Cerebral Balloon Angioplasty, Aneurysm Coiling, Neurothrombectomy Devices, Support Devices, Stenting Systems, Embolization Devices and Other Products), Application (Ischemic Stro

Neurovascular Devices Market Forecasts to 2028 – Global Analysis By Product (Cerebral Balloon Angioplasty, Aneurysm Coiling, Neurothrombectomy Devices, Support Devices, Stenting Systems, Embolization Devices and Other Products), Application (Ischemic Stroke, Cerebral Aneuryms, Carotid Artery Stenosis and Arteriovenous Malformations & Fistulas), End User (Hospitals, Speciality Clinics, Ambulatory Care Centers and Other End Users), and By Geography

According to Stratistics MRC, the Global Neurovascular Devices Market is accounted for $2.76 billion in 2022 and is expected to reach $5.06 billion by 2028 growing at a CAGR of 10.6% during the forecast period. Neurovascular problems are treated with neurovascular devices. The neurovascular illnesses might cause the patient to experience significant disability or perhaps pass away because they are brought on by inadequate or constrained blood and oxygen supply to the brain. Strokes, brain aneurysms, arteriovenous malformations, and stenosis can result from this. The global prevalence of neurovascular illnesses is driving acceleration in the market for neurovascular devices. In order to diagnose and treat disorders of the brain and central nervous system, neurological gadgets are routinely utilised. Because of advances in technology in neurology, there is a growing demand for neurovascular devices.

According to the Brain Aneurysm Foundation, 6 million Americans are thought to experience brain aneurysms annually. Additionally, every year, the illness kills half a million people worldwide. These trends are creating a sizable patient population that needs medical attention.

Market Dynamics:

Driver:

Rise in the number of strokes

The incidence of strokes worldwide has been rising as a result of a number of causes, including growing urbanisation, an inactive lifestyle and stress. Such changes are creating a huge patient population that needs medical attention. This is expected to further accelerate the growth of the neurovascular devices market during the projected period, along with rising patient awareness regarding the accessibility of treatment and reimbursement for neurovascular illnesses, particularly in emerging nations. Governments and non-profit organizations from developing nations are actively interested in educating the general public about the different forms of neurovascular illnesses, their symptoms, the precautions to take in an emergency, and the available treatments which are accelerating the market growth.

Restraint:

Strict regulations

One of the main factors limiting the global market for neurovascular devices is the high cost of neurovascular surgical procedures and equipment, particularly in developing nations with lax reimbursement systems. Additionally, the total cost of ownership of these devices rises due to maintenance costs and other related indirect costs, which restricts their adoption. Budgetary restrictions make it more difficult for small hospitals and independent ASCs to purchase expensive and complex technologies this problem is more pronounced in developing nations. Only a very small number of patients in impoverished nations can afford neurological treatment due to exorbitant costs and a weak reimbursement environment. As a result, healthcare facilities are hesitant to spend money on novel or cutting-edge technical solutions, which restricts the market for neurovascular devices.

Opportunity:

Insurance Coverage for Neurovascular Devices

Patients have a heavy financial burden for stroke treatment in developed countries. Therefore, the acceptance of neurovascular devices in this country has been greatly influenced by the availability of insurance coverage through public and private health insurance. Government and non-government groups have taken steps to improve and execute insurance coverage policies for the treatment of neurovascular illnesses in rising Asia-Pacific nations like China and Japan. It is anticipated that this factor would result in more people receiving therapy encouraging the market growth.

Threat:

Strict regulations

Various major producers of neurovascular devices, including Stryker and Medtronic Plc, have had success in the previous ten years with the creation and subsequent commercialization of their individual products. These goods were primarily made for usage abroad during neurovascular operations. However, in mature countries, pricing pressure experienced by the major product makers as a result of unfavourable government reforms implemented in the previous three years is the principal factor affecting the development pipeline for worldwide neurology goods.

Covid-19 Impact

The COVID-19 pandemic has had a negative impact on the neurovascular devices market which caused disruption, constraints, difficulties, and adjustments in every industry's sector. Similar to this, the pandemic also had an effect on the neurovascular devices industry. Neurovascular devices, for instance, are employed during surgical procedures. As a result, the neurovascular market has been negatively impacted by the limited accessibility of medical care for disorders other than COVID-19 globally. Another component that has an adverse impact on the market for neurovascular devices is the restricted supply of healthcare workers globally. Thus all the above impacts have hampered the market growth.

The embolization devices segment is expected to be the largest during the forecast period

The embolization devices segment is estimated to have a lucrative growth, due to the extensive R&D activity growth, increased awareness in less invasive procedures, and technological advancements in embolization products and techniques. Patients' choices for various diseases are shifting in recent years to choose minimally invasive therapies. Moreover, since the recovery time is less than with conventional open procedures, it is safer. Embolization is another minimally invasive technique used to stop the blood flow to abnormal tissue tumours. The market is growing as a result of patients' changing preferences toward less invasive embolization. The market for embolization is predicted to grow as demand for minimally invasive procedures increases in turn helps in growth of the neurovascular devices market.

The ischemic stroke segment is expected to have the highest CAGR during the forecast period

The ischemic stroke segment is anticipated to witness the fastest CAGR growth during the forecast period; due to the widespread increase in the prevalence of ischemic stroke and the accessibility of novel technologies for the condition's treatment and aspects that are expected to drive the market expansion for neurovascular devices used in interventional neurology. About 87% of strokes, according to the Centers for Disease Control and Prevention, are brought on by a blockage in cerebral blood flow. The American Heart Association also suggests using stent retrieval tools to remove blood clots from patients to help patients avoid having an ischemic stroke. Thus, it is projected that during the forecast period, demand for neurovascular devices will increase as ischemia cases rise.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the number of geriatrics with neurovascular diseases is growing quickly. For instance, the Asia Pacific region's geriatric population is growing at an unprecedented rate, and it is predicted that by 2050, one in four persons in this region would be over 60. This is according to the United Nations Population Fund. Additionally, the Asia Pacific market is anticipated to increase as a result of the emerging markets in various nations, including Japan, China, and India. Due to the expanding health care infrastructure and rising prevalence of neurovascular diseases, Asia pacific region is anticipated to show considerable market growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the rising incidence of neurovascular disorders and the strong demand for minimally invasive procedures. For instance, the Centers for Disease Control and Prevention estimate that more than 795,000 strokes, or approximately 87% of all strokes, occur in the Europe each year. In addition, it is anticipated that the use of neuro interventional devices would increase over the course of the projection period due to rising healthcare costs and the widespread use of technologically sophisticated systems in nations like Germany, France and Italy regions are propelling the market growth.

Key players in the market

Some of the key players profiled in the Neurovascular Devices Market include Johnson & Johnson Services, Inc., Medtronic, Penumbra, Inc, Terumo Corporation, MicroPort Scientific Corporation, Shape Memory Medical, Imperative Care, Integer Holdings Corporation, ASAHI INTECC CO., LTD, Stryker, Microvention Inc, Codman Neuro, Merit Medical Systems, W.L.Gore & Associates, Inc and Acandis GmbH.

Key Developments:

In Dec 2022, Johnson & Johnson the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.

In Dec 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow up.

In Dec 2022, the Johnson & Johnson announced updated results from the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody. Talquetamab targets both GPRC5D, a novel target on multiple myeloma cells, and CD3 on T cells, activating the body’s immune system to fight this blood cancer.

In Dec 2022, Medtronic announces first patient enrolled in U.S. clinical trial for Hugo™ robotic-assisted surgery system the Hugo™ RAS system is intended to be used in this study for urologic surgical procedures including radical prostatectomy, radical cystectomy, and nephrectomy (partial or radical) procedures at sites in the U.S.

Products Covered:
• Cerebral Balloon Angioplasty
• Aneurysm Coiling
• Neurothrombectomy Devices
• Support Devices
• Stenting Systems
• Embolization Devices
• Other Products

Applications Covered:
• Ischemic Stroke
• Cerebral Aneuryms
• Carotid Artery Stenosis
• Arteriovenous Malformations & Fistulas

End Users Covered:
• Hospitals
• Speciality Clinics
• Ambulatory Care Centers
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements